# A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

> **NCT05736835** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CyanVac LLC** · enrollment: 227 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CVXGA

## Key facts

- **NCT ID:** NCT05736835
- **Lead sponsor:** CyanVac LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736835, "A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05736835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*